Search Results - "Serebruany, V"

Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified by Serebruany, V L

“…The PLATO trial revealed excess all-cause (4.5%) and vascular (4.0%) mortality after experimental pyrimidine, ticagrelor, and even higher death rates (5.9% and…”
Get more information

Dyspnoea after antiplatelet agents: the AZD6140 controversy by Serebruany, V L, Stebbing, J, Atar, D

“…Recent randomised studies suggest that experimental oral reversible platelet P2Y12 receptor inhibitor, AZD6140, causes dyspnoea. This also raises similar…”
Get more information

Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel by Malinin, A, Pokov, A, Swaim, L, Kotob, M, Serebruany, V

“…Despite common use of clopidogrel in patients with vascular disease, monitoring of platelet inhibition is still not conventional in clinical practice…”
Get full text

Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study by Serebruany, V L, Midei, M G, Meilman, H, Malinin, A I, Lowry, D R

“…Background: Based on the preclinical and phase 1 studies, prasugrel, a novel platelet ADP P2Y12 receptor blocker, may be a more potent platelet inhibitor than…”
Get full text

Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease by Serebruany, V L, Malinin, A, Barsness, G, Vahabi, J, Atar, D

“…Aliskiren, an octanamide, is nonpeptide, low molecular weight, orally active renin inhibitor effectively preventing angiotensin and aldosterone release. This…”
Get full text

Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors by Malinin, A I, Ong, S, Makarov, L M, Petukhova, E Y, Serebruany, V L

“…Aspirin, dipyridamole, cilostazol, thienopyridines and glycoprotein IIb/IIIa inhibitors represent the classical examples of the established antiplatelet agents…”
Get more information

The TRITON versus PLATO trials: differences beyond platelet inhibition by Serebruany, V L

“…Clopidogrel monopoly as an exclusive oral antiplatelet agent used in combination with aspirin or as a monotherapy for treatment or/and prevention of occlusive…”
Get more information

Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial by Serebruany, V L, Midei, M G, Meilman, H, Malinin, A I, Lowry, D R

“…Therapy with aspirin and/or adenosine diphosphate (ADP) receptor blockers is associated with better outcomes via inhibition of platelet activity, and…”
Get more information

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial by SAW, Jacqueline, STEINHUBL, Steven R, BERGER, Peter B, KEREIAKES, Dean J, SEREBRUANY, Victor L, BRENNAN, Danielle, TOPOL, Eric J

“…Statins primarily metabolized by cytochrome P450 3A4 (CYP3A4) reportedly reduce clopidogrel's metabolism to active metabolite, thus attenuating its inhibition…”
Get full text

Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure by O’Connor, Christopher M, Gurbel, Paul A, Serebruany, Victor L

“…P-selectin is an important marker of platelet activation and may be up-regulated in patients with congestive heart failure (CHF). We sought to prospectively…”
Get full text

Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy by Serebruany, Victor L, Glassman, Alexander H, Malinin, Alex I, Nemeroff, Charles B, Musselman, Dominique L, van Zyl, Louis T, Finkel, Mitchell S, Krishnan, K Ranga R, Gaffney, Michael, Harrison, Wilma, Califf, Robert M, O'Connor, Christopher M

“…Depression after acute coronary syndromes (ACSs) has been identified as an independent risk factor for subsequent cardiac death. Enhanced platelet activation…”
Get full text

Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin by Serebruany, V.L., Glassman, A.H., Malinin, A.I., Atar, D., Sane, D.C., Oshrine, B.R., Ferguson, J.J., O'Connor, C.M.

“…Clinical depression has been identified as an independent risk factor for increased mortality in patients with coronary artery disease. Enhanced platelet…”
Get full text

The differences between the guidelines of the European Society of Cardiology and the American College of Cardiology/ American Heart Association for oral P2Y12 inhibitor therapy in the management of patients with acute coronary syndromes by Serebruany, V L, Pershukov, I V

“…The analysis of the evidence that formed the basis for the current guidelines of the European Society of Cardiology (ESC) on oral therapy by antithrombotic…”
Get more information

Effects of Reteplase and Alteplase on Platelet Aggregation and Major Receptor Expression During the First 24 Hours of Acute Myocardial Infarction Treatment by Gurbel, Paul A., Serebruany, Victor L., Shustov, Andrew R., Bahr, Raymond D., Carpo, Cynthia, Ohman, E.Magnus, Topol, Eric J.

“…Objectives. We sought to compare platelet characteristics after reteplase and alteplase therapy in the setting of the Global Use of Strategies to Open Occluded…”
Get full text

Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives by Serebruany, Michael V, Malinin, Alex I, Serebruany, Victor L

“…Heparin remains the most commonly used anticoagulant in the treatment of patients with acute vascular syndromes, including myocardial infarction, unstable…”
Get more information

Noncompliance in antiplatelet trials: the AGATE trial perspective by Serebruany, V L, Hanley, Jr, D F, Atar, D, Ferguson, J J

Get full text

Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department by Gurbel, Paul A, Kereiakes, Dean J, Dalesandro, Margaret R, Bahr, Raymond D, O'Connor, Christopher M, Serebruany, Victor L

“…Background It has been reported that selectins participate in the pathogenesis of acute coronary syndromes by modulating platelet-leukocyte-endothelium…”
Get full text

Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors by Nair, G V, Gurbel, P A, O'Connor, C M, Gattis, W A, Murugesan, S R, Serebruany, V L

“…There is substantial clinical evidence that the incidence of depression and mortality after acute coronary events are strongly related. As mediators of…”
Get full text

Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction by Serebruany, Victor L., Gurbel, Paul A., Shustov, Andrew R., Ohman, E.Magnus, Topol, Eric J.

“…Background Platelets play an important role in the natural history of acute myocardial infarction (AMI). Methods and Results Platelet aggregation and receptor…”
Get full text

The challenge of monitoring platelet response after clopidogrel by Serebruany, Victor L., Goto, Shinya

Get full text